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Abstract
Background: The clinical significance of SPINK1 intronic variants in chronic pancreatitis has been previously assessed
by various approaches including a cell culture-based full-length gene assay. A close correlation between the results of
this assay and in silico splicing prediction was apparent. However, until now, a clinical diagnostic pipeline specifically
designed to classify SPINK1 intronic variants accurately and efficiently has been lacking. Herein, we present just such a
pipeline and explore its efficacy and potential utility in potentiating the classification of newly described SPINK1 intronic
variants.
Results: We confirm a close correlation between in silico splicing prediction and results from the cell culture-based
full-length gene assay in the context of three recently reported pathogenic SPINK1 intronic variants. We then integrated
in silico splicing prediction and the full-length gene assay into a stepwise approach and tested its utility in
the classification of two novel datasets of SPINK1 intronic variants. The first dataset comprised 16 deep intronic variants
identified in 52 genetically unexplained Chinese chronic pancreatitis patients by sequencing the entire intronic
sequence of the SPINK1 gene. The second dataset comprised five novel rare proximal intronic variants identified
through the routine analysis of the SPINK1 gene in French pancreatitis patients. Employing a minor allele frequency of
> 5% as a population frequency filter, 6 of the 16 deep intronic variants were immediately classified as benign. In silico
prediction of the remaining ten deep intronic variants and the five rare proximal intronic variants with respect to their
likely impact on splice site selection suggested that only one proximal intronic variant, c.194 + 5G > A, was likely to be
of functional significance. Employing the cell culture-based full-length gene assay, we functionally analyzed
c.194 + 5G > A, together with seven predicted non-functional variants, thereby validating their predicted effects
on splicing in all cases.
Conclusions: We demonstrated the accuracy and efficiency of in silico prediction in combination with the
cell culture-based full-length gene assay for the classification of SPINK1 intronic variants. Based upon these
findings, we propose an operational pipeline for classifying SPINK1 intronic variants in the clinical diagnostic
setting.
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Background
Chronic pancreatitis has traditionally been defined as a
chronic inflammatory process of the pancreas that leads
to progressive and irreversible impairment of both exo-
crine and endocrine functions, with a focus on morpho-
logical changes. More recently, the disease has been
redefined as a “pathologic fibro-inflammatory syndrome
of the pancreas in individuals with genetic, environmen-
tal and/or other risk factors who develop persistent
pathologic responses to parenchymal injury or stress”,
with a focus on underlying pathogenic mechanisms [1].
In particular, genetic studies over the past two decades
have underscored the importance of a trypsin-dependent
pathway in the etiology of the disease [2–5]. One of the
most extensively studied pancreatitis susceptibility genes,
SPINK1 (encoding pancreatic secretory trypsin inhibitor;
MIM# 167790), is characterized by a diverse range of re-
ported variants from point mutations to whole gene de-
letions (for a complete list, see ref. [6]). Pathogenic
SPINK1 variants predispose to pancreatitis by lowering
the inhibitory capacity of prematurely activated trypsin
within the pancreas. The clinical relevance of canonical
splice site variants, nonsense mutations, or large-scale
genomic deletions in the SPINK1 gene is generally clear.
By contrast, the clinical relevance of SPINK1 promoter
and enhancer variants [7–9], missense variants [10, 11],
or intronic variants occurring outwith the canonical
splice sites [12, 13] has often had to be ascertained by in
vitro functional analysis.
In silico splicing prediction programs have been widely
used to evaluate the functional effects of intronic vari-
ants in clinical genetics, either on their own or in com-
bination with an in vitro splicing assay [14, 15]. In this
regard, we have previously employed a cell culture-based
full-length gene assay to systematically assess the func-
tional impact of a series of SPINK1 intronic variants [12,
13] and, more recently, we have noted a close correl-
ation between the results from this assay and in silico
splicing predictions [16]. The full-length gene assay has
at least two advantages over the commonly used mini-
gene splicing assay. First, the full-length gene assay pre-
serves better the natural genomic context of the studied
variants, a point of key importance given the highly
context-dependent nature of splicing regulation [17].
Second, the full-length gene splicing assay can be readily
used to evaluate intronic variants located near the first
exon or last exon of the gene; by contrast, special adap-
tation of the minigene would normally be required for
such variants to be analyzed, as exemplified by a recent
publication [18].
SPINK1 intronic variants continue to be reported in
the literature [19–22] and additional SPINK1 intronic
variants, including those located in deep intronic re-
gions, are certainly likely to emerge with the application
of high-throughput whole-genome sequencing [23]. To
rise to this challenge, establishment of a clinical diagnos-
tic pipeline for the classification of SPINK1 intronic vari-
ants is required. The aim of the present study was to
develop such a pipeline and assess its efficacy and utility.
To this end, we further explored the correlation of in
silico splicing prediction and our cell-based full-length
gene assay in the context of three recently reported
pathogenic SPINK1 variants. Then we integrated both
the in silico splicing prediction procedure and the
full-length gene assay into a stepwise approach in order
to classify a series of SPINK1 intronic variants newly dis-
covered in Chinese and French pancreatitis patients.
Results and discussion
Further correlation of in silico splicing prediction and
functional assay data in the context of three recently
reported SPINK1 splice site variants
Before going into the detail of the current study, we
would like to make two points. The first refers to the ex-
perimental evaluation of the functional effect of intronic
variants. Ideally, the disease-affected tissue/cells or sur-
rogate tissue/cells that also highly express the gene of
interest from the patients should be analyzed whenever
possible. SPINK1 mRNA is most abundantly expressed
in the pancreas, with a median transcripts per kilobase
million (TPM) of 4361 in accordance with the
Genotype-Tissue Expression (GTEx) dataset [24]. Stom-
ach ranks second for SPINK1 mRNA expression, al-
though the corresponding TPM is only 285 [24]. Neither
tissue, but particularly the pancreas, is accessible in
practice in terms of biopsy samples. The next and most
commonly used strategy is to perform a splicing assay in
a transient expression system, in which human cell lines
of pathophysiological relevance should be employed
whenever possible owing to the tissue specificity of the
splicing process in some instances (see [25] and refer-
ences therein). Unfortunately, no human pancreatic aci-
nar cell lines are currently available. In the present
study, we used human embryonic kidney 293 T
(HEK293T) cells for the splicing assay as previously de-
scribed [12, 13, 16]. It is possible that splicing in
HEK293T cells may not always reflect the in vivo situ-
ation, a general drawback of splicing assay that employ
non-pathophysiologically relevant cells [26].
The second point refers to in silico prediction of the
impact of intronic variants on splicing. Of particular
relevance, we have previously observed a close correl-
ation of results from our full-length gene assay with
those from the in silico splicing predictions in the con-
text of 24 SPINK1 intronic variants [16]. Findings per-
taining to two variants merit especial attention. First,
c.194 + 2T > C (or IVS3 + 2T > C) was shown to retain
partial ability to generate wild-type transcripts by reverse
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transcription-polymerase chain reaction (RT-PCR) ana-
lysis of patient-derived stomach tissue [27] and also by
our full-length gene assay [12]. It was predicted to be as-
sociated with only an ~ 12% decrease in the score for
SpliceSiteFinder-like (wild-type score of 82.6 vs mutant
score of 72.3) but invariably a score of 0 for MaxEntS-
can, NNSPLICE, and Human Splicing Finder [16]. Both
predictions were correct, depending on one’s viewpoint.
Thus, the prediction of SpliceSiteFinder-like was correct
from the standpoint that c.194 + 2T > C was able to gen-
erate an appreciable level of wild-type transcript; the
predictions of MaxEntScan, NNSPLICE, and Human
Splicing Finder were correct from the standpoint that
c.194 + 2T > C resulted in a significantly reduced level of
normally spliced SPINK1 transcript as compared to that
of the wild-type allele. The second case involved the
c.194 + 13T > G variant, which was predicted by different
programs to generate a new and viable donor splice site
but resulted in the generation of a trace amount of aber-
rantly spliced transcripts that was only detectable using
specially designed allele-specific primers [16]. With
hindsight, these two particular cases might reflect a limi-
tation in splicing prediction programs analogous to that
seen in missense variant prediction programs: “The main
issue lies within the binary output of most models,
which predict whether or not a variant has an effect but
not its magnitude” [28]. Nonetheless, at least in the con-
text of the 24 SPINK1 intronic variants analyzed [16],
the in silico prediction tools were collectively not found
to yield false negative findings.
Bearing in mind the aforementioned considerations, we
decided to further explore the cross-correlation of in silico
predictions and our full-length gene splicing assay in the
context of three recently reported SPINK1 splice site vari-
ants, c.55 + 1G >A [19], c.194 + 1G >A [20], and c.88-1G >
A [22]. These three variants are of unequivocally clinical
significance by virtue of their disruption of splice site con-
sensus sequences (Additional file 1: Figure S1), as predicted
by SpliceSiteFinder-like, MaxEntScan, NNSPLICE, and
GeneSplicer, made available via the Alamut software suite,
under default conditions [29].
We then characterized the splicing defects associated
with the three splice site variants by means of our previ-
ously established cell culture-based full-length gene assay
[12, 13]. RT-PCR analysis of HEK293T cells transfected
with the full-length SPINK1 gene construct harboring the
c.55 + 1G >A variant showed two aberrant transcripts
(Fig. 1a). Subsequent sequencing revealed that the shorter
transcript resulted from the activation of a cryptic splice
donor site within exon 1 (at position c.7_8), resulting in
the deletion of the 3′ end of exon 1; the longer transcript
resulted from activation of a cryptic splice acceptor site
within intron 1 (at position c.55 + 141_55 + 142), resulting
in the insertion of the 5′ end of intron 1 into the tran-
script (Fig. 2).
The c.194 + 1G > A variant was found to result in the
generation of a single aberrant transcript (Fig. 1a), in
which exon 3 was skipped (Fig. 2).
The c.88-1G > A variant [22] was found to be in cis
with c.88-7 T > A, located only five bases away (Add-
itional file 1: Figure S2). Given that neither of these two
variants is present in the Genome Aggregation Database
(genomAD) [30], it is possible that they were generated
simultaneously as a single mutational event [31, 32]. Ir-
respective of whether or not the two variants were gen-
erated simultaneously, they should be named c.[88-1G >
A; 88-7 T > A] in accordance with the Human Genome
Variation Society (HGVS) recommendations [33].
The c.[88-1G > A; 88-7 T > A] variant is very likely to
affect splicing due to the c.88-1G > A component
(Additional file 1: Figure S1). However, the splicing out-
come of the c.88-1G > A variant may be modified by the
a
b
Fig. 1 Results from the cell culture-based full-length gene assay. a, b RT-PCR analyses of HEK293T cells transfected with full-length SPINK1 gene
expression constructs carrying respectively the wild-type and indicated intronic variants. Normal transcripts (confirmed by sequencing) are indicated by
arrows. In b, the lower bands generated by c.194 + 2 T > C and c.194 + 5G > A were found to be identical by sequencing, with exon 3 being skipped.
See Fig. 2 for the precise splicing outcomes of the three recently reported SPINK1 splice site variants
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juxtaposition of the c.88-7 T > A variant, even although
the latter on its own was predicted not to significantly
affect splice site selection (Additional file 1: Figure S3).
To explore this possibility, we compared the splicing
outcomes in vitro of c.88-1G > A alone, c.88-7 T > A
alone, and c.[88-1G > A; 88-7 T > A]. RT-PCR analyses of
HEK293T cells transfected with the corresponding
full-length gene constructs invariably generated a single
band of similar size to that of the wild-type (Fig. 1a).
Subsequent sequencing revealed that c.88-1G > A alone
and c.[88-1G > A; 88-7 T > A] alone resulted in identical
skipping of the first nucleotide of exon 3 (i.e., the splice
Fig. 2 Splicing outcomes of the three recently reported SPINK1 splice site variants as determined by the cell culture-based full-length gene assay.
Normal splicing in the context of the wild-type sequence and aberrant splicing in the context of the mutant sequence are illustrated for each of
the three variants. The splice donor signal (GT) and splice acceptor signal (AG) are highlighted in blue. Variants occurred within the splice sites are
highlighted in green. In c.55 + 1G > A, the two novel splice donor sites used for aberrant splicing are highlighted in red. In c.[88-1G > A;
88-7 T > A], the c.88-1G > A variant shifted the AG site by one base, resulting in the skipping of the first nucleotide of exon 3 (i.e., the G
highlighted in red). S shorter, L longer, M mutant
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site was shifted by one nucleotide; Fig. 2) of the SPINK1
gene while c.88-7 T > A alone generated only wild-type
transcripts. Consequently, it may be concluded that the
functional effect of c.[88-1G > A; 88-7 T > A] was con-
ferred solely by the c.88-1G > A variant.
Taken together, we have provided further evidence for
a good correlation between in silico splicing predictions
and our functional assay of SPINK1 intronic variants. In-
deed, our cell culture-based full-length gene assay not
only validated the predicted impact on splicing but also
elucidated the precise mRNA splicing consequences of
specific pathogenic variants. The latter is key to under-
standing the genotype-phenotype relationship since ab-
errantly spliced transcripts may not invariably lead to
the synthesis of proteins characterized by complete
loss-of-function.
Integration of splicing prediction and functional assay
into a stepwise procedure for classifying newly found
SPINK1 variants
Data directly comparing the incidences and clinical fea-
tures of chronic pancreatitis between Chinese and Euro-
pean populations are lacking. By contrast, marked ethnic
differences were noted between them in terms of genetic
predisposition to the disease, exemplified by three recent
findings: the CEL-HYB risk allele [34] was found to be ab-
sent in the Chinese population [35]; rare functional CPA1
variants [36] were not enriched in Chinese chronic pan-
creatitis patients [37]; and the common CTRB1-CTRB2
inversion allele [38] did not contribute to disease risk in
the Chinese population due to near allele fixation [39].
Significant differences also exist between Chinese and
European populations in terms of the spectrum and fre-
quency of variants in each of the four firmly established
pancreatitis susceptibility genes (i.e., SPINK1 [40], PRSS1
[41], CTRC [42, 43], and CFTR [44, 45]) [22].
A comprehensive analysis of the SPINK1, PRSS1,
CTRC, and CFTR genes in 253 young French chronic
pancreatitis revealed that ~ 52% of the studied patients
remained genetically unexplained [46]. Remarkably, the
proportion of Chinese patients that remained genetically
unexplained after mutational analysis of the above four
genes (i.e., ~ 50%) [22] is quite comparable to that in the
French patients. As part of our attempt to identify the
“missing heritability,” we performed targeted resequen-
cing of the deep intronic sequence of the SPINK1 gene
in 52 genetically unexplained Chinese chronic pancrea-
titis patients using previously described methods [13].
[Note that the proximal intronic regions of the SPINK1
gene had previously been analyzed [22].] This resulted in
the identification of 16 deep SPINK1 intronic variants
(Table 1). In addition, during the routine analysis of the
SPINK1 gene (focusing on coding and proximal intronic
sequences) in French pancreatitis patients, we identified
five rare proximal SPINK1 intronic variants that had not
previously been described in the literature (Table 2). In
the five respective French carriers, no known disease-
causing variants in the PRSS1 gene were found but other
pancreatitis susceptibility genes remain to be analyzed.
This does not affect the conclusion of the present study
in any way.
In the following sections, we describe how we attempted
to integrate in silico splicing predictions and our
full-length gene assay into a stepwise approach to classify
the above two datasets of SPINK1 intronic variants.
First step: population frequency filtering
Demonstrating the functionality of a given variant is a
prerequisite for any claim of pathogenicity to be cred-
ible. A primary consideration when predicting whether a
variant is likely to have a functional effect is its popula-
tion frequency [47]; the rarer the variant, the more likely
it is to exert a pathogenic effect. A minor allele fre-
quency (MAF) of > 1% in the control population is the
most frequently used threshold for defining “common”
variants. Here, we employed a conservative threshold, a
MAF of > 5%, for population frequency filtering, using
data from genomAD [30] as a reference. Using allele fre-
quency in the East Asian population as a filter would
have resulted in 6 of the 16 deep intronic variants found
in the Chinese patients being classified as benign
(Table 1). Indeed, all six of these common variants have
previously been described and annotated as benign in
the Genetic Risk Factors in Chronic Pancreatitis Data-
base [6]. It should be noted that in the case of four of
the six common variants, it is the minor allele that is
used as the reference sequence. We did not attempt to
convert the corresponding major allele frequencies to
the alternative MAFs in these cases (Table 1).
Second step: in silico prediction on splice site selection
None of the remaining ten deep SPINK1 intronic variants,
all of which had an allele frequency of < 5% in the East
Asian population (Table 1), have been previously de-
scribed in the Genetic Risk Factors in Chronic Pancreatitis
Database [6]. These variants, together with the five rare
proximal variants found in the French patients (Table 2),
were subjected to in silico splicing prediction (i.e., disrup-
tion of known splice sites or creation of novel splice sites
were sought) by means of SpliceSiteFinder-like, MaxEntS-
can, NNSPLICE, and GeneSplicer made available via the
Alamut software suite, under default conditions [29].
However, only the proximal c.194 + 5G >A variant was
predicted to be of functional significance by virtue of it
significantly reducing the splice site consensus scores (de-
fined here as a reduction of ≥ 10% of the wild-type value
across all four prediction programs) as compared to the
wild-type allele (Fig. 3). By contrast, none of the ten rare
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deep intronic variants found in Chinese patients or the
other four rare proximal variants found in French patients
were predicted to significantly reduce the splice site con-
sensus scores or generate a novel splice site (Additional
file 1: Figures S4 and S5). Additionally, we performed the
same predictions for the six common deep SPINK1 in-
tronic variants (Table 1) but none were predicted to have
a functional effect (Additional file 1: Figure S6). In short,
of the 16 common and 5 rare SPINK1 intronic variants,
the proximal c.194 + 5G > A variant was the only one pre-
dicted to be of functional significance (Tables 1 and 2).
Third step: functional validation
We performed functional analysis of the predicted func-
tionally significant c.194 + 5G > A variant by means of
our cell culture-based full-length gene assay. We also
Table 1 SPINK1 deep intronic variants found in the 52 Chinese patients with chronic pancreatitis
Intron Variant No. of
carriersa
Allele frequency
in patients
Allele frequency
in the East Asian
populationb
rs number In silico
predictionc
In vitro
validationcDNA numbering gDNA numbering
(chr 5, hg19)
Minor allele frequency of ≥ 5% (all have previously been described [3])
2 c.88-352A > G g.147208043 T > C 51 (37 hom.) 0.846 0.819d rs6580502 No effect Not done
3 c.194 + 1159C > G g.147206426G > C 10 0.096 0.070 rs1897577 No effect Not done
3 c.195-1645G > C g.147205914C > G 43 (17 hom.) 0.577 0.571d rs17717320 No effect Not done
3 c.195-1570C > A g.147205839G > T 44 (22 hom.) 0.635 0.619d rs17703305 No effect Not done
3 c.195-478 T > G g.147204747A > C 10 0.096 0.070 rs17774073 No effect Not done
3 c.195-323C > T g.147204592G > A 44 (21 hom.) 0.625 0.618d rs4705202 No effect Not done
Minor allele frequency of < 5% (all have not previously been described [3])
1 c.56-609G > C g.147209802C > G 1 0.00962 Absent from genomAD Not available No effect Not done
1 c.56-324 T > A g.147209517A > T 2 0.01923 0.00963 rs546549375 No effect Yes
3 c.194 + 671C > T g.147206914G > A 1 0.00962 0.00193 rs889082209 No effect Not done
3 c.194 + 723C > T g.147206862G > A 1 0.00962 0.00193 rs573757839 No effect Not done
3 c.194 + 855G > A g.147206730C > T 1 0.00962 0.00705 rs543534355 No effect Not done
3 c.194 + 1278C > T g.147206307G > A 3 0.02885 0.01797 rs118005432 No effect Yes
3 c.194 + 1599G > A g.147205986C > T 1 0.00962 Absent from genomAD Not available No effect Not done
3 c.195-1414 T>Ae g.147205683A>Te 1 0.00962 0.00000f rs2436411e No effect Yes
3 c.195-862 T > C g.147205131A > G 1g 0.01923 Absent from genomAD Not available No effect Yes
3 c.195-854C > T g.147205123G > A 1 0.00962 0.00062 rs1055746254 No effect Yes
aNumber of homozygotes (hom.) is indicated in parentheses wherever applicable
bData are in accordance with genomAD (as of October 31, 2018)
cEffect on spice site selection predicted by SpliceSiteFinder-like, MaxEntScan, NNSPLICE and GeneSplicer under default conditions
dThe alternative minor allele frequency is of ≥ 5%
eIn hg19, the reference sequence at this position is the minor allele sequence
fAbsent in the East Asian population but present in other population(s)
gThe carrier is a homozygote. The presence of a large deletion spanning the position of interest cannot be excluded
Table 2 Rare proximal SPINK1 intronic variants found in French pancreatitis patients
Region Varianta Allele frequency in the
European (non-Finnish)
populationb
rs number In silico predictionc In vitro
validationcDNA numbering gDNA numbering (chr5, hg19)
Intron 2 c.87 + 13 T > G g.147209149A > C Absent from genomAD Not available No effect Yes
Intron 2 c.88-48C > A g.147207739G > T 0.00001 rs753830042 No effect Yes
Intron 3 c.194 + 5G > A g.147207580C > T Absent from genomAD Not available Significantly reduced the score
for the c.194 + 2 splice site
Yes
Intron 3 c.194 + 32 T > C g.147207553A > G 0.00000d rs770552173 No effect Not done
Intron 3 c.195-21 T > A g.147204290A > T 0.00014 rs377350168 No effect Not done
aEach variant was found once in some 4000 patients subjected to routine analysis of the SPINK1 gene. None of the variants have been described in the Genetic
Risk Factors in Chronic Pancreatitis Database [6] (as of October 29, 2018)
bData in accordance with genomAD (as of October 31, 2018)
cEffect on splice site selection as predicted by SpliceSiteFinder-like, MaxEntScan, NNSPLICE and GeneSplicer under default conditions
dAbsent in the European (non-Finnish) population but present in other population(s)
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included, as negative controls, seven variants predicted
to be non-functional (including both deep and proximal
variants; Tables 1 and 2), as a means to cross-correlate
in silico prediction and the results of our functional
assay. RT-PCR analyses of the respectively transfected
HEK293T cells confirmed the splicing predictions in all
cases. Thus, a single transcript of similar size to the
wild-type was observed in all seven predicted
non-functional variants (i.e., c.56-324 T > A, c.194 +
1278C > T, c.195-1414 T > A, c.195-862 T > C, and
c.195-854C > T in Fig. 1a; and c.87 + 13 T > G and
c.88-48C > A in Fig. 1b); subsequent sequencing con-
firmed that all these transcripts were identical to the
wild-type sequence. By contrast, c.194 + 5G > A gener-
ated a splicing pattern that was very similar to that of
the pathogenic c.194 + 2 T > C variant [12], comprising a
normally spliced band and an aberrantly spliced band
(exon 3 skipped). It should be noted that the c.194 +
5G > A variant retained fewer normally spliced tran-
scripts as compared to the c.194 + 2 T > C variant
(Fig. 1b), an observation that argues for it being a novel
pathogenic variant.
The precise splicing outcomes of pathogenic SPINK1
intronic variants described to date are summarized in
Table 3. All these pathogenic intronic variants are lo-
cated either in the canonical splice sites or very close to
Fig. 3 Splicing effect of the proximal c.194 + 5G > A variant as predicted by the Alamut software suite
Table 3 Precise splicing outcomes of the pathogenic SPINK1 intronic variants described to date
Region Variant nomenclaturea Description on splicing mechanisms and
outcomes
Reference pertaining
to functional analysisAt DNA level At RNA level At protein level
Intron 1 c.55 + 1G > A r.7_55del; and r.55_
56ins55 + 1_55 + 140
p.Gly5Leufs*74; and
p.Gly19Aspfs*11
Activation of a cryptic splice donor site
within exon 1 (at position c.7_8), resulting
in the deletion of the 3′ end of exon 1;
and activation of a cryptic splice acceptor
site within intron 1 (at position c.55 + 141
_55 + 142), resulting in the insertion of the
5′ end of intron 1 into the transcript
This study
Intron 2 c.87 + 1G > A r.56_87del p.Asn20Glnfs*5 Exon 2 skipping [12]
Intron 2 c.[88-1G > A; 88-7 T > A] r.88del p.Ala30Profs*65 Skipping of the first nucleotide of exon 3
(the functional effect was derived entirely
from the c.88_1G > A component variant)
This study
Intron 3 c.194 + 1G > A r.88_194del p.Ala30Glufs*35 Complete exon 3 skipping This study
Intron 3 c.194 + 2 T > C r.88_194del p.Ala30Glufs*35 Skipping of exon 3 in 90% of transcripts [12]
Intron 3 c.194 + 5G > A r.88_194del p.Ala30Glufs*35 Almost complete exon 3 skipping This study
aVariant nomenclature followed HGVS recommendations (http://www.hgvs.org/mutnomen/)
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the exon/intron junctions. This concurs with findings
from many disease genes, probably for two reasons:
splice-defining cis-acting sequence elements are predom-
inantly located within proximal intronic regions [48] and
the large size of the intronic regions renders routine
screening impractical. In this regard, take two examples of
recent large-scale analyses, one in the context of human
cancer [49] and the other in the context of Stargardt dis-
ease [26]: none of the intronic variants under study were
located within deep intronic regions. This notwithstand-
ing, pathogenic variants do occur within deep intronic re-
gions, and are often discovered by transcript analysis or
whole-genome sequencing (e.g., [50–52]). In terms of their
functional consequences, pathogenic variants in deep in-
tronic regions often appear to be able to generate some
wild-type transcripts (e.g., all three USH2A deep intronic
variants reported in [50] were shown to do so in a mini-
gene assay). In terms of their clinical consequences, patho-
genic variants in deep intronic regions may be associated
with a broad phenotypic spectrum, as exemplified by three
CFTR deep intronic variants [52]. Pathogenic variants in
the deep intronic regions of the SPINK1 gene may be
identified in the future, when whole-genome sequencing
is routinely used for clinical diagnosis.
Finally, it is pertinent to mention that any SPINK1 in-
tronic variant that has been classified as benign may ac-
tually occur in cis with a functional variant located
elsewhere in the coding sequence or regulatory regions
of the gene. In order to explore this possibility, we
searched all the currently studied SPINK1 intronic vari-
ants with a known rs number (Tables 1 and 2) in the
GTEx dataset [24]. Only three SNPs, rs6580502,
rs17703305, and rs4705202, all of which have a MAF of
> 5 in the general population, were associated with a re-
duced SPINK1 expression; all the expression data were
obtained from the lung tissue.
Conclusions
In the context of three recently reported SPINK1 splice
site variants, we have provided further evidence for a
close correlation between in silico splicing predictions
and the results of our functional assay of SPINK1 in-
tronic variants. In the context of two new datasets of
SPINK1 intronic variants, we then demonstrated the ac-
curacy and efficiency of in silico splicing prediction in
combination with the cell culture-based full-length gene
assay in variant classification. In so doing, we elucidated
the precise splicing consequences of the three recently
reported SPINK1 splice site variants and identified and
functionally characterized a novel pathogenic variant,
c.194 + 5G > A. Based on the findings of this study and
previous studies, we propose the following clinical diag-
nostic pipeline for classifying SPINK1 intronic variants.
The first step applies a population frequency filter using
data in genomAD as a reference and employing a con-
servative MAF of ≥ 5% as a threshold. In the second
step, the impact of the remaining rare variants on splice
site selection is predicted. These two steps proved highly
effective at classifying most of the detected SPINK1 in-
tronic variants as benign. Thus, in practice, only a very
small number of SPINK1 intronic variants (those pre-
dicted to affect splice site selection) actually needed to
be functionally validated. We believe that the application
of this procedure will greatly facilitate the classification of
SPINK1 intronic variants in a clinical diagnostic setting.
This notwithstanding, it should be noted that the number
of in-parallel tested SPINK1 intronic variants is still rela-
tively small. Consequently, we would recommend that
functional analysis be employed once an intronic variant
is suggested to be of functional significance by two or even
one splicing prediction programs. Moreover, the threshold
MAF for population frequency filtering (the reference
population must be the same as the proband population)
may be redefined as more data become available. Finally,
it should be appreciated that an accurate determination of
the pathogenic relevance of any SPINK1 intronic variant
in chronic pancreatitis is not only important from a mech-
anistic viewpoint [1] but also provides potential thera-
peutic targets as shown in other genes (e.g., [51, 53]).
Methods
Identification of SPINK1 intronic variants in Chinese and
French pancreatitis patients
Fifty-two Han Chinese chronic pancreatitis patients,
whose age of disease onset was known to be ≤ 20 years or
whose disease diagnosis was made at ≤ 20 years, partici-
pated this study. These patients, whose pancreatitis had
remained genetically unexplained after mutational analysis
of the entire coding regions and exon/intron boundaries
of four pancreatitis susceptibility genes (i.e., SPINK1 [40],
PRSS1 [41], CTRC [42, 43], and CFTR [44, 45]) [22], were
searched for possible pancreatitis-predisposing variants
occurring within deep SPINK1 intronic regions in accord-
ance with previously described procedures [13]. Proximal
SPINK1 intronic variants were identified through routine
mutational screening of the entire coding region and
exon/intron boundaries of the SPINK1 gene in French
pancreatitis patients by means of high-resolution DNA
melting (HRM) analysis [54]. All SPINK1 intronic variants
were subjected to independent PCR amplification and
Sanger sequencing. Informed consent was obtained from
each participant. This study was approved by the respect-
ive Ethics Committees of Changhai Hospital in Shanghai
and the University Hospital in Brest.
Nomenclature of SPINK1 intronic variants
Nomenclature for the description of SPINK1 intronic se-
quence variants followed HGVS recommendations [33].
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It should however be noted that whereas the SPINK1 gene
comprises five exons, in accordance with mRNA reference
sequence accession NM_003122.3, the gene expressed in
the exocrine pancreas comprises only four exons [55, 56].
It is the latter gene structure that is used by both pancrea-
titis genetics researchers [6, 9, 13, 40, 57] and Ensembl
(refer to ENSG00000164266) [58]. The traditional IVS
(InterVening Sequence; i.e., an intron) nomenclature for
describing SPINK1 intronic variants corresponds to the
four-exon gene structure. In this study, in accordance with
convention, we used the four-exon gene structure of
pathophysiological relevance to define SPINK1 intron
numbers. Thus, in the current work, the SPINK1 gene is
regarded as harboring three introns. Since the first exon
in accordance with mRNA reference sequence accession
NM_003122.3 is non-coding, the variant nomenclature
following HGVS recommendations is unaffected.
Allele frequency reference
Data in genomAD [30] were used as a reference for
population frequency filtering.
In silico prediction of impact on splice site selection
In silico prediction of the impact of specific variants on
splice site choice was performed using Alamut® Visual
v.2.11 rev. 0 that included four prediction algorithms viz.
SpliceSiteFinder-like, MaxEntScan, NNSPLICE and Gen-
eSplicer under default conditions [29].
Cell culture-based full-length gene assay
The wild-type expression vector harboring the full-
length genomic SPINK1 gene has been previously de-
scribed [59]. It was used to generate the full-length ex-
pression constructs harboring respectively the selected
SPINK1 intronic variants by means of the Quik-
Change II XL Site-Directed Mutagenesis Kit (Agilent
Technologies). In vitro mutagenesis, HEK293T cell
culture, transfection, RT-PCR, and real-time quantita-
tive RT-PCR analyses were performed essentially as
previously described [12, 16].
Additional files
Additional file 1: Figure S1. Alamut-predicted impact on splice site
selection of the three recently reported SPINK1 spice site variants.
Figure S2. Presence of the c.88-1G > A (chr5:g.147207692C > T) in cis
with a closely spaced variant, c.88-7 T > A (chr5:g.147207698A > T), in
a Chinese patient with chronic pancreatitis. Figure S3. Alamut-predicted
impact on splice site selection of the proximal c.88-7 T > A variant. Figure
S4. Alamut-predicted impact on splice site selection of the 10 deep SPINK1
intronic variants with a minor allele frequency of < 5% in the East Asian
population. Figure S5. Alamut-predicted impact on splice site selection of
the other four proximal SPINK1 intronic variants found in the French
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site selection of the six deep SPINK1 intronic variants with a minor allele
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